Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1–CREB1 fusion and ALK overexpression

Grinda, Thomas; Boilève, Alice; Lévy, Antonin; Lepéchoux, C.; Haddag, Leila; Valent, Alexander; Lazure, Thierry; Briand, Sylvain; Honoré, Charles; Faron, Matthieu; Mir, Olivier; Bahleda, Ratio; Verret, Benjamin; Cesne, Axel Le

doi:10.1016/j.annonc.2022.05.003

Cited by 9 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with crizotinib has shown efficacy in a variety of ALK mutant and rearranged tumors including non‐small‐cell lung cancer (NSCLC), inflammatory myofibroblastic tumors, and neuroblastoma, 8 , 9 , 10 and now, there is emerging evidence of the effectiveness of ALK inhibitors in the treatment of tumors with ALK overexpression without mutation or fusion. 11 , 12 While PNET is a distinct entity from neuroblastoma, there are shared biological and molecular characteristics that make the finding of oncogenic ALK expression less surprising in the case presented here. It has been shown that embryonic neuroblasts and neural crest cells rely on ALK‐ and MYC‐pathway activation to maintain differentiation during embryonic development.…”

Section: Discussionmentioning

confidence: 74%

“…This is the first report of a PNET treated with targeted tyrosine kinase inhibitor (TKI) therapy. Treatment with crizotinib has shown efficacy in a variety of ALK mutant and rearranged tumors including non‐small‐cell lung cancer (NSCLC), inflammatory myofibroblastic tumors, and neuroblastoma, 8–10 and now, there is emerging evidence of the effectiveness of ALK inhibitors in the treatment of tumors with ALK overexpression without mutation or fusion 11,12 . While PNET is a distinct entity from neuroblastoma, there are shared biological and molecular characteristics that make the finding of oncogenic ALK expression less surprising in the case presented here.…”

Section: Discussionmentioning

confidence: 76%

See 1 more Smart Citation

Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response

Snyder

Lion

Helvie

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Discussionmentioning

confidence: 76%

Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response

Snyder

Lion

Helvie

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…In the head and neck area, performing a wide excision is often clinically impossible and is associated with disease recurrence in the future. However, local recurrence of the lesion depends on the size and depth of tissue invasion[ 11 ] and occurs in 15%[ 13 ] or, according to another source, in 2%-12% of cases[ 5 ].…”

Section: Discussionmentioning

confidence: 99%

Difficulties in diagnosing angiomatoid fibrous histiocytoma of the head and neck region: A case report

Michcik,

Bień,

Wojciechowska

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

Fasting during the month of Ramadan is one of the five fundamental principles of Islam, and it is obligatory for healthy Muslim adults and adolescents. During the fasting month, Muslims usually have two meals a day, suhur (before dawn) and iftar (after dusk). However, diabetic patients may face difficulties when fasting, so it is important for medical staff to educate them on safe fasting practices. Prolonged strict fasting can increase the risk of hypoglycemia and diabetic ketoacidosis, but with proper knowledge, careful planning, and medication adjustment, diabetic Muslim patients can fast during Ramadan. For this review, a literature search was conducted using PubMed and Google Scholar until May 2023. Articles other than the English language were excluded. Current strategies for managing blood sugar levels during Ramadan include a combination of patient education on nutrition, regular monitoring of blood glucose, medications, and insulin therapy. Insulin therapy can be continued during fasting if properly titrated to the patients’ needs, and finger prick blood sugar levels should be assessed regularly. If certain symptoms such as hypoglycemia, hyperglycemia, dehydration, or acute illness occur, or blood glucose levels become too high (> 300 mg/dL) or too low (70 mg/dL), the fast should be broken. New insulin formulations such as pegylated insulin and medications like tirzepatide, a dual agonist of gastric-inhibitory peptideand glucagonlike-peptide 1 receptors, have shown promise in managing blood sugar levels during Ramadan. Non-insulin-dependent medications like sodium-glucose-cotransporter-2 inhibitors, including the Food and Drug Administration-approved ertugliflozin, are also being used to provide additional cardiovascular benefits in patients with type 2 diabetes.

show abstract

“…This is the first report of a PNET treated with targeted tyrosine kinase inhibitor (TKI) therapy. Treatment with crizotinib has shown efficacy in a variety of ALK mutant and rearranged tumors including non-small cell lung cancer (NSCLC), inflammatory myofibroblastic tumors, and neuroblastoma [7][8][9] and, now there is emerging evidence of the effectiveness of ALK-inhibitors in the treatment of tumors with ALK overexpression without mutation or fusion [10,11]. While PNET is a distinct entity from neuroblastoma, there are shared biologic and molecular characteristics that make the finding of oncogenic ALK expression less surprising in the case presented here.…”

Section: Discussionmentioning

confidence: 99%

Targeted Treatment of Refractory PNET Arising from An Immature Teratoma with Crizotinib Leading to a Sustained Response

Snyder

Lion

Helvie

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1–CREB1 fusion and ALK overexpression

Cited by 9 publications

References 12 publications

Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response

Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response

Difficulties in diagnosing angiomatoid fibrous histiocytoma of the head and neck region: A case report

Targeted Treatment of Refractory PNET Arising from An Immature Teratoma with Crizotinib Leading to a Sustained Response

Contact Info

Product

Resources

About